dc.contributor
Institut Català de la Salut
dc.contributor
[Arriola E] Medical Oncology Department, Hospital del Mar, Center for Biomedical Network Research on Cancer (CIBERONC), Barcelona, Spain. [de Castro J] Medical Oncology Department, La Paz University Hospital, Hospital La Paz Health Research Institute (IdiPAZ), Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain. [García Campelo R] Medical Oncology Department, A Coruña University Hospital, Biomedical Research Institute of A Coruña (INIBIC), A Coruña, Spain. [Bernárdez B] Oncological Pharmacy Unit, Santiago de Compostela University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, A Coruña, Spain. [Bernabé R] Medical Oncology Department, Virgen del Rocío University Hospital, Biomedicine Institute of Sevilla (IBIS), University of Sevilla, Sevilla, Spain. [Bruna J] Neuro-Oncology Unit, Bellvitge University Hospital, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Bernardez, Beatriz
dc.contributor.author
Bruna, Jordi
dc.contributor.author
Arriola, Edurne
dc.contributor.author
De Castro, Javier
dc.contributor.author
Garcia Campelo, Rosario
dc.contributor.author
Bernabé, Reyes
dc.contributor.author
FELIP, ENRIQUETA
dc.date.issued
2025-02-12T13:37:02Z
dc.date.issued
2025-02-12T13:37:02Z
dc.identifier
Arriola E, de Castro J, García-Campelo R, Bernárdez B, Bernabé R, Bruna J, et al. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. Clin Drug Investig. 2024 Aug;44(8):553–76.
dc.identifier
https://hdl.handle.net/11351/12591
dc.identifier
10.1007/s40261-024-01379-7
dc.identifier
001281860100001
dc.description.abstract
Consenso; Eventos adversos; Cáncer de pulmón de células no pequeñas
dc.description.abstract
Consens; Esdeveniments adversos; Càncer de pulmó de cèl·lules no petites
dc.description.abstract
Consensus; Adverse events; Non-small cell lung cancer
dc.description.abstract
The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts.
dc.description.abstract
This project was developed with funding from Pfizer.
dc.format
application/pdf
dc.relation
Clinical Drug Investigation;44(8)
dc.relation
https://doi.org/10.1007/s40261-024-01379-7
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Decisió de grup
dc.subject
Proteïnes quinases - Inhibidors - Ús terapèutic - Efectes secundaris
dc.subject
Pulmons - Càncer - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptor Protein-Tyrosine Kinases::Anaplastic Lymphoma Kinase
dc.subject
Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores proteína-tirosina cinasas::cinasa del linfoma anaplásico
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores
dc.title
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
